Drug-gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP Inhibition.
Kunzah JamalAlessandro GalbiatiJoshua ArmeniaGiuditta IlluzziJames A HallSabrina BentouatiDaniel BarrellMiika Ahdesmäkinull nullLenka Oplustil O'ConnorElisabetta LeoJosep V FormentPublished in: Cancer research communications (2022)
as a potential biomarker of PARPi sensitivity in prostate cancer.